Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.
Animals
COVID-19
/ complications
Endothelin Receptor Antagonists
/ therapeutic use
Humans
Phosphodiesterase Inhibitors
/ therapeutic use
Prostaglandins
/ therapeutic use
Pulmonary Artery
/ drug effects
Pyrazoles
/ therapeutic use
Pyrimidines
/ therapeutic use
Respiratory Distress Syndrome
/ complications
COVID-19 Drug Treatment
ARDS
COVID-19
Endothelin receptor antagonists
Epoprostenol
PDE-5 inhibitors
Riociguat
Journal
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
ISSN: 1950-6007
Titre abrégé: Biomed Pharmacother
Pays: France
ID NLM: 8213295
Informations de publication
Date de publication:
Feb 2022
Feb 2022
Historique:
received:
18
11
2021
revised:
22
12
2021
accepted:
23
12
2021
entrez:
22
1
2022
pubmed:
23
1
2022
medline:
29
1
2022
Statut:
ppublish
Résumé
The most grievous complication of the COVID-19 is the acute respiratory distress syndrome. A specific, rescue treatment for rapidly deteriorating patients should emerge to improve respiratory function and help patients to survive the most challenging period. Drugs used in targeted therapy of pulmonary arterial hypertension (PAH) appears to be suitable for this task and this article describes their potential for treatment of severe cases of COVID-19. The authors reviewed the following databases for randomized controlled trials, reviews and meta-analyses published up to July 2020: Pubmed, Scopus, Google Scholar, Cochrane Database and ClinicalKey. The authors included every study contributory to the assessment of the potential of drugs used in targeted PAH therapy in treatment of COVID-19. Endothelin receptor antagonists, phosphodiesterase 5 inhibitors, riociguat and prostacyclin have proven ani-inflammatory effect and reduce pulmonary artery blood pressure, lung oedema and remodelling. Bosentan shows antiviral properties and sildenafil, as well as epoprostenol, inhibits apoptosis of lung epithelial cells. Among patients with lung lesions the decrease of pulmonary blood pressure can lead to increase of ventilation/perfusion mismatch and decrease of blood oxygenation. Among all assessed drugs bosentan, sildenafil and epoprostenol appear to be most promising and a combination of these drugs should be considered due to synergism. The targeted PAH therapy in treatment of COVID-19 associated ARDS could be a useful tool saving lives of patients with severe SARS-CoV-2 infection, however, its introduction should be investigated and monitored very carefully as it can lead to transient deterioration of patient condition.
Identifiants
pubmed: 35062063
pii: S0753-3322(21)01379-2
doi: 10.1016/j.biopha.2021.112592
pmc: PMC8709827
pii:
doi:
Substances chimiques
Endothelin Receptor Antagonists
0
Phosphodiesterase Inhibitors
0
Prostaglandins
0
Pyrazoles
0
Pyrimidines
0
riociguat
RU3FE2Y4XI
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
112592Informations de copyright
Copyright © 2021 The Authors. Published by Elsevier Masson SAS.. All rights reserved.
Références
PLoS One. 2018 Jul 10;13(7):e0199927
pubmed: 29990355
Lung. 2019 Dec;197(6):753-760
pubmed: 31583452
Br J Pharmacol. 2008 Dec;155(7):984-94
pubmed: 18846041
Eurasian J Med. 2020 Feb;52(1):81-85
pubmed: 32158321
Am J Physiol Lung Cell Mol Physiol. 2000 Sep;279(3):L496-502
pubmed: 10956624
N Engl J Med. 2013 Jul 25;369(4):330-40
pubmed: 23883378
J Cardiovasc Pharmacol. 2000;35(4 Suppl 2):S49-53
pubmed: 10976782
Intensive Care Med. 2010 May;36(5):758-64
pubmed: 20130830
J Endocrinol Invest. 2021 Feb;44(2):223-231
pubmed: 32661947
Ann Thorac Surg. 1996 Nov;62(5):1494-9
pubmed: 8893590
Nature. 2012 Dec 6;492(7427):123-7
pubmed: 23143333
Andrology. 2021 Jan;9(1):33-38
pubmed: 32526061
PLoS One. 2018 Jan 24;13(1):e0191239
pubmed: 29364918
Surgery. 1997 Aug;122(2):196-202; discussion 202-3
pubmed: 9288123
Heart Fail Rev. 2001 Dec;6(4):253-64
pubmed: 11447300
Heart Fail Rev. 2001 Dec;6(4):325-34
pubmed: 11447307
Crit Care. 2020 May 6;24(1):198
pubmed: 32375845
Computation (Basel). 2020 Jun;8(2):
pubmed: 32661494
Basic Clin Pharmacol Toxicol. 2018 Aug;123(2):103-113
pubmed: 29719121
Am J Ther. 2019 Jul/Aug;26(4):e520-e526
pubmed: 30946047
Transplant Proc. 2017 Jul - Aug;49(6):1461-1466
pubmed: 28736024
Orv Hetil. 2020 Apr 01;161(17):704-709
pubmed: 32324366
Vasc Health Risk Manag. 2015 May 14;11:265-70
pubmed: 25999730
J Endocrinol Invest. 2019 Jun;42(6):715-725
pubmed: 30415310
J Clin Virol. 2020 Jun;127:104371
pubmed: 32315817
Cleve Clin J Med. 2020 May 11;:
pubmed: 32393596
Biochem Pharmacol. 2016 Sep 15;116:188-99
pubmed: 27422754
Med Hypotheses. 2020 Oct;143:109851
pubmed: 32534175
Curr Pharmacol Rep. 2020;6(3):56-70
pubmed: 32395418
Heart Dis. 2003 Mar-Apr;5(2):161-9
pubmed: 12713683
J Surg Res. 2008 Nov;150(1):66-73
pubmed: 18468638
Curr Med Chem. 2011;18(23):3506-15
pubmed: 21756232
Diseases. 2018 May 16;6(2):
pubmed: 29772649
J Mol Med (Berl). 2019 Feb;97(2):201-213
pubmed: 30535954
J Cardiovasc Pharmacol. 2000 Nov;36(5 Suppl 1):S371-3
pubmed: 11078423
Inflammation. 2016 Jun;39(3):1238-52
pubmed: 27165639
J Cardiovasc Pharmacol. 2013 Jul;62(1):1-5
pubmed: 23232843
Am J Respir Crit Care Med. 2000 Sep;162(3 Pt 1):850-6
pubmed: 10988094
Cancer Prev Res (Phila). 2017 Jul;10(7):377-388
pubmed: 28468928
Pharmacol Rep. 2008 Jan-Feb;60(1):3-11
pubmed: 18276980
Pharmacology. 2015;96(3-4):144-50
pubmed: 26226834
Pulm Pharmacol. 1994 Dec;7(6):409-13
pubmed: 7549229
Prostaglandins Other Lipid Mediat. 2018 May;136:33-43
pubmed: 29660395
Am J Cancer Res. 2017 Jan 01;7(1):41-52
pubmed: 28123846
Am J Health Syst Pharm. 2017 Aug 1;74(15):1135-1141
pubmed: 28533253
J Gen Virol. 2010 Aug;91(Pt 8):1959-1970
pubmed: 20392896
Int Immunopharmacol. 2016 Nov;40:530-541
pubmed: 27769022
J Appl Physiol (1985). 1994 Jan;76(1):345-55
pubmed: 8175528
Lung. 2014 Oct;192(5):635-6
pubmed: 24898108
J Heart Lung Transplant. 2020 Jul;39(7):729-730
pubmed: 32360293
BMC Urol. 2019 Oct 23;19(1):99
pubmed: 31646996
Eur J Pharmacol. 2015 Dec 5;768:123-30
pubmed: 26526351
Am J Cardiovasc Drugs. 2019 Apr;19(2):99-105
pubmed: 30671881
Sci China Life Sci. 2020 Mar;63(3):364-374
pubmed: 32048163
Med Hypotheses. 2020 Aug;141:109792
pubmed: 32361169
Arthritis Res Ther. 2011 Jun 20;13(3):R97
pubmed: 21689431
Pol Arch Intern Med. 2021 Sep 30;131(9):854-861
pubmed: 34590451
Mol Med Rep. 2018 Nov;18(5):4399-4409
pubmed: 30152849
Clin Respir J. 2018 Jun;12(6):2065-2074
pubmed: 29393580
Basic Clin Pharmacol Toxicol. 2020 Jan;126(1):32-42
pubmed: 31403254
N Engl J Med. 2002 Aug 1;347(5):322-9
pubmed: 12151469
Ther Adv Respir Dis. 2015 Dec;9(6):302-12
pubmed: 26294418
Am Rev Respir Dis. 1993 Nov;148(5):1169-73
pubmed: 8239149
Br J Pharmacol. 2005 Sep;146(1):109-17
pubmed: 15980872
J Surg Res. 1997 Aug;71(2):145-9
pubmed: 9299282
Immunol Res. 2016 Feb;64(1):303-12
pubmed: 26616294
J Physiol Pharmacol. 2018 Oct;69(5):
pubmed: 30683832